palbociclib
pfizer
['breast', 'ibrance', 'dial', 'pfizer']
in the latest in a series of big clinical setbacks, pfizer reported at #asco22 that its phiii study of ibrance combined with femara failed to significantly move the dial on survival for first-line cases of metastatic breast cancer compared to femara alone. 
The biopharma world is here. Get the industry’s most comprehensive daily news report at https://t.co/rXFyNyZcJs